<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Moleculin Biotech ( (MBRX) ) has provided an update. On May 13, 2026, Moleculin Biotech reported that it is nearing the first unblinding of data from its pivotal Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine in relapsed or refractory acute myeloid leukemia, with the initial 45-patient unblinding expected before June 30, 2026. The adaptive, global, randomized study compares two dosing arms of Annamycin plus cytarabine to cytarabine with placebo, and is enrolling second-line AML patients, including those previously treated with Venetoclax. The company said blinded efficacy data from the first 45 subjects show a composite complete remission rate above 40% and a complete remission rate near 30%, markedly higher than the roughly 17–18% historical complete remission rates seen with cytarabine alone in similar populations. With 56 of the planned 90 Part A subjects already recruited as of May 1 and no cardiotoxicity reported so far, Moleculin is signaling that Annamycin could represent a significant advance over standard cytarabine regimens for this high-unmet-need AML group and help support its push toward potential regulatory approval. The most recent analyst rating on (MBRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page. Spark’s Take on MBRX Stock According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral. The score is held back primarily by weak financial performance (no revenue, sustained losses, and continued cash burn with financing dependence). Offsetting factors include multiple positive corporate developments around Annamycin (trial progress/safety and strengthened patent coverage), while technicals are broadly neutral and valuation signals are hard to rely on given the pre-revenue profile. To see Spark’s full report on MBRX stock, click here. More about Moleculin Biotech Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company developing therapeutics for hard-to-treat tumors and viruses, with a lead program centered on Annamycin, an anthracycline designed to avoid multidrug resistance and cardiotoxicity. Annamycin is being developed for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases, alongside additional oncology and antiviral candidates including WP1066 and WP1122 in its broader pipeline. Average Trading Volume: 175,330 Technical Sentiment Signal: Sell Current Market Cap: $12.49M </div>

MBRX

SBIO

LABU

Moleculin Biotech (MBRX) is nearing the first unblinding of data from its pivotal Phase 2B/3 MIRACLE trial for Annamycin plus cytarabine in treating relapsed or refractory acute myeloid leukemia, with results expected before June 30, 2026. Initial data shows a composite complete remission rate above 40%, significantly higher than historical rates with cytarabine alone. The company is progressing towards potential regulatory approval, despite current financial challenges. Analysts rate MBRX stock as a Buy with a $22.00 price target, while AI analysis suggests a Neutral outlook due to financial performance concerns.

Moleculin Nears First Unblinding in Pivotal MIRACLE Trial